Nicox S.A. (EPA:ALCOX)

Market Cap	22.09M
Revenue (ttm)	3.57M
Net Income (ttm)	-17.36M
Shares Out	72.20M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	5.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	965,002
Average Volume	561,736
Open	0.3100
Previous Close	0.3060
Day's Range	0.3060 - 0.3350
52-Week Range	0.1400 - 0.3630
Beta	0.88
RSI	75.38
Earnings Date	Jul 18, 2025

About Nicox

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 28
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCOX

Financial Performance

In 2022, Nicox's revenue was 3.27 million, a decrease of -54.78% compared to the previous year's 7.23 million. Losses were -27.76 million, -36.57% less than in 2021.